About: A Multiple siRNA-Based Anti-HIV/SHIV Microbicide Shows Protection in Both In Vitro and In Vivo Models

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Multiple siRNA-Based Anti-HIV/SHIV Microbicide Shows Protection in Both In Vitro and In Vivo Models Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A Multiple siRNA-Based Anti-HIV/SHIV Microbicide Shows Protection in Both In Vitro and In Vivo Models
Creator	Boyapalle, Sandhya Mohapatra, Subhra Xu, Mohapatra, Shyam Raulji,
Source	PMC
abstract	Human immunodeficiency virus (HIV) types 1 and 2 (HIV-1 and HIV-2) are the etiologic agents of AIDS. Most HIV-1 infected individuals worldwide are women, who acquire HIV infections during sexual contact. Blocking HIV mucosal transmission and local spread in the female lower genital tract is important in preventing infection and ultimately eliminating the pandemic. Microbicides work by destroying the microbes or preventing them from establishing an infection. Thus, a number of different types of microbicides are under investigation, however, the lack of their solubility and bioavailability, and toxicity has been major hurdles. Herein, we report the development of multifunctional chitosan-lipid nanocomplexes that can effectively deliver plasmids encoding siRNA(s) as microbicides without adverse effects and provide significant protection against HIV in both in vitro and in vivo models. Chitosan or chitosan-lipid (chlipid) was complexed with a cocktail of plasmids encoding HIV-1-specific siRNAs (psiRNAs) and evaluated for their efficacy in HEK-293 cells, PBMCs derived from nonhuman primates, 3-dimensional human vaginal ectocervical tissue (3D-VEC) model and also in non-human primate model. Moreover, prophylactic administration of the chlipid to deliver a psiRNA cocktail intravaginally with a cream formulation in a non-human primate model showed substantial reduction of SHIV (simian/human immunodeficiency virus SF162) viral titers. Taken together, these studies demonstrate the potential of chlipid-siRNA nanocomplexes as a potential genetic microbicide against HIV infections.
has issue date	2015-09-25(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0135288
bibo:pmid	26407080
has license	cc0
sha1sum (hex)	a5360f18c21cf7f9a04e9b21663301b4548eadd9
schema:url	https://doi.org/10.1371/journal.pone.0135288
resource representing a document's title	A Multiple siRNA-Based Anti-HIV/SHIV Microbicide Shows Protection in Both In Vitro and In Vivo Models
has PubMed Central identifier	PMC4583459
has PubMed identifier	26407080
schema:publication	PLoS One
resource representing a document's body	covid:a5360f18c21cf7f9a04e9b21663301b4548eadd9#body_text
is schema:about of	named entity 'effectively' named entity 'efficacy' named entity 'destroying' named entity 'PBMCs' named entity 'primates' named entity 'derived' named entity 'infections' named entity 'genital tract' named entity 'sexual' named entity 'cocktail' named entity 'SHIV' named entity 'Microbicide' named entity 'Multiple' named entity 'MODELS' named entity 'SIRNA' covid:arg/a5360f18c21cf7f9a04e9b21663301b4548eadd9 named entity 'HIV INFECTIONS' named entity 'ENCODING' named entity 'LOWER' named entity 'EFFICACY' named entity 'HIV-2' named entity 'GENETIC' named entity 'ESTABLISHING' named entity 'DESTROYING' named entity 'FEMALE' named entity 'DIFFERENT' named entity 'SIRNA' named entity 'MODELS' named entity 'EVALUATED' named entity 'PANDEMIC' named entity 'REDUCTION' named entity 'WORLDWIDE' named entity 'HIV' named entity 'IMMUNODEFICIENCY VIRUS' named entity 'SIGNIFICANT' named entity 'ACQUIRE' named entity 'TISSUE' named entity 'LIPID' named entity 'TAKEN' named entity 'VEC' named entity 'DELIVER' named entity 'SPECIFIC' named entity 'ADMINISTRATION' named entity 'IMPORTANT' named entity 'FORMULATION' named entity 'TYPES' named entity 'ECTOCERVICAL' named entity 'MODEL' named entity 'ADVERSE EFFECTS' named entity '28S' named entity 'INDIVIDUALS' named entity 'MAJOR' named entity 'REPORT' named entity 'PLASMIDS' named entity 'SEXUAL CONTACT' named entity 'TRANSMISSION' named entity 'AIDS' named entity 'PROVIDE' named entity 'CREAM' named entity 'HUMAN IMMUNODEFICIENCY VIRUS' named entity 'PREVENTING' named entity 'MICROBES' named entity 'MULTIPLE' named entity 'PROTECTION' named entity 'PROPHYLACTIC' named entity 'VIRAL' named entity 'PBMCS' named entity 'MICROBICIDE' named entity 'HEK-293' named entity 'LACK' named entity 'CELLS' named entity 'NONHUMAN PRIMATES' named entity 'HIV-1' named entity 'INFECTED' named entity 'SIRNAS' named entity 'ANTI-HIV' named entity 'BLOCKING'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software